Glucagon-like peptide-1 (GLP-1), another anorexigenic peptide, and GLP-1 receptor agonists (GLP-1R), represent potential therapeutic agents to prevent NAFLD progression to NASH. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.